3 Dividend Stocks Worth Buying Now?
Thanks to surging stock prices over the past two years, dividend yields on major stock indices have fallen to fairly low levels. The S&P 500, for instance, currently carries an average yield of just 1.3%.
The mature companies in the Dow Jones Industrial Average fare a bit better, and some of them offer yields that exceed the S&P 500 several times over. » Read more about: 3 Dividend Stocks Worth Buying Now? »
Read More
Sure Fire Way To Get $1,000 Income?
Want to lock in $1,000 of income quite predictably? One strategy now has the potential to do just that, and potentially a lot more by leveraging the current macroeconomic climate.
If you were to look at the world’s conflicts through the lens of a technical chart analyst, it wouldn’t be a stretch to see that the “conflict trend line”
» Read more about: Sure Fire Way To Get $1,000 Income? »
Read More
Is This The Perfect Bitcoin Strategy?
A decade or so ago, betting on bitcoin really was risky. The cryptocurrency was entirely unproven, unregulated, little-known and fraught with risk. Fast forward 10+ years and the times have changed substantially in favor of Satoshi’s creation.
Now exchange-traded funds exist that facilitate regular flows into the cryptocurrency and some companies, like Microstrategy,
» Read more about: Is This The Perfect Bitcoin Strategy? »
Read More
Don’t Be Fooled By Gold
Gold has been on a tear in recent months and rightly so, it seems, looking at macro events. What started as an Israeli-Palestine conflict has escalated to include Iran, which in turn is leading to speculation that the US may be get involved, and by then war appears to be a real possibility. Worse still are the prospects for further expansion if other countries are brought into the fray,
» Read more about: Don’t Be Fooled By Gold »
Read More
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Ivy
DoorDash’s Soaring Stock: A Smart Buy or a Bubble Waiting to Burst?
Gig economy food delivery service DoorDash (NASDAQ:DASH) has been running hot for most of the last year, gaining over 75 percent in the last 12 months. Such large increases, though, often leave stocks susceptible to corrections that bring their prices back down to earth. We examine DoorDash’s performance and valuation to see whether the stock is a buy,
» Read more about: DoorDash’s Soaring Stock: A Smart Buy or a Bubble Waiting to Burst? »
Read MoreThe Spotlight
How Do You Pick a Winning Stock?
Investors will often pour through dozens or even hundreds of stocks looking for the best investment options to add to their portfolios. Before doing this, however, it’s important to first understand what a good stock is.
Let’s take a look at some of the factors that define a good investment to understand what makes a potentially lucrative stock.
» Read more about: How Do You Pick a Winning Stock? »
Read MoreThe Daily
Maximizing Diversification With Alternative Investments For Stronger Portfolios
High net-worth investors (HNWI) are actively maximizing diversification in their portfolios beyond traditional stocks and bonds. Alternative investments are a significant area of focus. This includes inquiries about private equity, venture capital, private credit, real estate, hedge funds,
» Read more about: Maximizing Diversification With Alternative Investments For Stronger Portfolios »